CureVac N.V. (5CV.F)
EUR 2.72
(-2.01%)
EUR 2.72
(-2.01%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -274.2 Million EUR | -10.73% |
| 2022 | -249.45 Million EUR | 39.49% |
| 2021 | -412.26 Million EUR | -232.46% |
| 2020 | -124 Million EUR | -24.63% |
| 2019 | -99.49 Million EUR | -36.63% |
| 2018 | -72.82 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -74.68 Million EUR | -0.41% |
| 2024 Q1 | -73.31 Million EUR | 18.9% |
| 2023 Q2 | -71.8 Million EUR | -18.96% |
| 2023 FY | -276.22 Million EUR | -10.73% |
| 2023 Q1 | -60.35 Million EUR | 50.33% |
| 2023 Q4 | -90.4 Million EUR | -67.3% |
| 2023 Q3 | -54.03 Million EUR | 24.74% |
| 2022 Q3 | -52.38 Million EUR | 13.13% |
| 2022 Q2 | -60.29 Million EUR | -294.94% |
| 2022 Q1 | -15.26 Million EUR | -177.05% |
| 2022 FY | -249.45 Million EUR | 39.49% |
| 2022 Q4 | -121.51 Million EUR | -131.98% |
| 2021 Q1 | -115.83 Million EUR | -148.57% |
| 2021 Q3 | -143.09 Million EUR | 3.2% |
| 2021 Q2 | -147.82 Million EUR | -27.62% |
| 2021 FY | -412.26 Million EUR | -232.46% |
| 2021 Q4 | -5.51 Million EUR | 96.15% |
| 2020 Q4 | -46.6 Million EUR | -26.78% |
| 2020 Q3 | -36.75 Million EUR | -1048.69% |
| 2020 Q2 | -3.2 Million EUR | 86.22% |
| 2020 Q1 | -23.21 Million EUR | 33.8% |
| 2020 FY | -124 Million EUR | -24.63% |
| 2019 Q1 | -21.72 Million EUR | 0.0% |
| 2019 Q3 | -19.14 Million EUR | 0.0% |
| 2019 FY | -99.49 Million EUR | -36.63% |
| 2019 Q4 | -35.07 Million EUR | -83.19% |
| 2018 FY | -72.82 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| BioNTech SE | 690.4 Million EUR | 139.717% |
| Biotest Aktiengesellschaft | 143.5 Million EUR | 291.085% |
| Biotest Aktiengesellschaft | 143.5 Million EUR | 291.085% |
| BRAIN Biotech AG | -6.71 Million EUR | -3983.5% |
| Formycon AG | -369 Thousand EUR | -74210.84% |
| Heidelberg Pharma AG | -21.2 Million EUR | -1192.832% |
| Medigene AG | -16.14 Million EUR | -1597.981% |